Metformin for Pre-eclampsia Prevention in Type 1 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if metformin, a medication commonly used for diabetes, can prevent high blood pressure during pregnancy in women with type 1 diabetes. Pregnant women with type 1 diabetes face a high risk of complications like high blood pressure, which can endanger both mother and baby. The trial will compare the effects of adding metformin to usual care against usual care alone. Eligible participants are women who are 12 to 19 weeks pregnant and have a pre-pregnancy diagnosis of type 1 diabetes. As a Phase 4 trial, this research seeks to understand how the already FDA-approved and effective metformin can benefit more patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.
What is the safety track record for metformin?
Research has shown that metformin is generally safe during pregnancy. Studies have found it can help reduce weight gain in pregnant women, indicating good tolerance. One study focused on women with diabetes and found that metformin did not increase the risk of high blood pressure during pregnancy.
The FDA has approved metformin for managing type 2 diabetes, confirming its safety for that condition. It has been used in pregnant women with diabetes, and data consistently show it is safe for both mothers and babies.
Overall, metformin appears to be a safe option for pregnant women, including those with type 1 diabetes, though individual experiences may vary.12345Why are researchers enthusiastic about this study treatment?
Unlike the standard care for pre-eclampsia in type 1 diabetes, which often involves medications to manage blood pressure and close monitoring, metformin offers a unique approach. Researchers are excited about metformin because it targets insulin sensitivity, which is a different mechanism compared to traditional treatments. This could potentially address the underlying metabolic issues linked to pre-eclampsia in those with type 1 diabetes, offering a more targeted and proactive solution. Additionally, metformin is well-known and widely used, which might make it a more accessible and safe option for pregnant women.
What evidence suggests that metformin might be an effective treatment for pre-eclampsia prevention in type 1 diabetes?
Research suggests that metformin, which participants in this trial may receive, could help prevent high blood pressure problems during pregnancy, especially for women with diabetes. In women without diabetes, studies have shown that metformin might lower the risk of these pregnancy-related issues. Metformin is considered safe to use during pregnancy and has been well-researched for treating type 1 diabetes outside of pregnancy. It reduces certain proteins linked to high blood pressure during pregnancy. Overall, metformin has proven effective and safe for similar conditions, making it a promising option for preventing pre-eclampsia in pregnant women with type 1 diabetes.12678
Who Is on the Research Team?
Maisa N Feghali, MD
Principal Investigator
University of Pittsburgh
Are You a Good Fit for This Trial?
This trial is for pregnant women aged 18-50 with type 1 diabetes, between 12 and just under 20 weeks of gestation. It's not suitable for those with multiple pregnancies, kidney issues, significant protein in urine, liver disease, inflammatory bowel disease, major blood disorders or known metformin allergies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily oral metformin therapy initiated prior to 20 weeks' gestation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Metformin
Metformin is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
Maisa N. Feghali, MD
Lead Sponsor